摘要
【摘要】 目的：观察研究恩度联合化疗治疗中晚期非小细胞肺癌的临床治疗效果。方法：选取 2018年 2月 -2020年 2月笔者所在科接收治疗的中晚期非小细胞肺癌患者共 82例，采取数字随机法随机分为观察组、对照组两组，对照组患者采取 NP方案进行化疗，观察组患者采取恩度静滴联合 NP方案化疗进行治疗，在完成两个周期的治疗后对两组患者的近期治疗效果和不良反应给予评价并对比。结果：观察组患者的临床治疗有效率为 53.66%，对照组患者的临床治疗有效率为 41.46%，观察组的治疗效果明显优于对照组（ P<0.05）；经过两个周期的治疗，观察组患者的不良反应发生率为 19.51%，对照组患者的不良反应发生率为 21.96%，两组患者的相关不良反应率比较差异无统计学意义（ P>0.05）。结论：对中晚期非小细胞肺癌采取恩度静滴联合化疗进行治疗，不仅可以取得较显著的治疗效果，同时不良反应发生率较低，具有临床推广价值。
【关键词】 恩度； 化疗； 晚期非小细胞肺癌； 疗效
Objective: To observe the clinical effect of Endostar combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: a total of 82 patients with advanced non-small cell lung cancer in our department from February 2018 to February 2020 were selected and randomly divided into observation group and control group by digital random method. Patients in the control group were treated with NP regimen, while patients in the observation group were treated with Endostar intravenous drip combined with NP regimen chemotherapy. After two cycles of treatment, the short-term treatment of the two groups of patients was given The therapeutic effect and adverse reactions were evaluated and compared. Results: the clinical effective rate of the observation group was 53.66%, and that of the control group was 41.46%. The treatment effect of the observation group was significantly better than that of the control group (P < 0.05). After two cycles of treatment, the incidence of adverse reactions in the observation group was 19.51%, while that of the control group was 21.96%. The related adverse reaction rates of the two groups were relatively poor The difference was not statistically significant (P > 0.05). Conclusion: Endostar intravenous drip combined with chemotherapy in the treatment of advanced non-small cell lung cancer can not only achieve a significant therapeutic effect, but also has a low incidence of adverse reactions, which is worthy of clinical promotion.
出版日期
2020年09月27日（中国期刊网平台首次上网日期，不代表论文的发表时间）
